Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial
The landscape of clinical trials aimed at targeting specific proteins has experienced significant advancements, presenting promising opportunities for the development of effective therapeutics across a range of diseases. These trials focus on the investigation of modulation of protein functions, uti...
Saved in:
Main Authors: | Ela Kacin, Raj Nayan Sewduth |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/6/744 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Negative Immune Checkpoint Inhibitors
by: Magda Drewniak-Świtalska, et al.
Published: (2025-05-01) -
Harnessing the therapeutic potential of bacterial extracellular vesicles via functional peptides
by: Yejiao Shi, et al.
Published: (2025-07-01) -
Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for osteoporosis
by: Chiyun Sun, et al.
Published: (2025-06-01) -
PROTAC-Based Antivirals for Respiratory Viruses: A Novel Approach for Targeted Therapy and Vaccine Development
by: Amith Anugu, et al.
Published: (2025-07-01) -
Cancer Specific CAIX‐Targeting Supramolecular Lysosome‐Targeting Chimeras (Supra‐LYTAC) for Targeted Protein Degradation
by: Dohyun Kim, et al.
Published: (2025-07-01)